METHODS
The Swedish Alzheimer Treatment Study (SATS) is a prospective, observational, multicenter study for the long-term assessment of ChEI therapy in a routine clinical setting. This presentation includes information about 220 deceased SATS participants who had been clinically diagnosed with mild-to-moderate AD (Mini-Mental State Examination (MMSE) score, 10-26 at the start of ChEI treatment) who were admitted to NHs during the study. Cognitive status (MMSE) and functional performance (Instrumental Activities of Daily Living scale (IADL) and Physical Self-Maintenance Scale (PSMS)) were evaluated at the start of ChEI therapy (about the time of AD diagnosis) and semiannually over 3 years. Concomitant medications and dates of nursing home placement (NHP) and death were recorded. The choice of drug agent and all decisions regarding dosage for each individual patient were left entirely to the discretion and professional judgment of dementia specialists.
A t-test (Figure 1 ) and one-way analysis of variance (ANOVA) with Bonferroni correction (Figures 2-4 ) were used to compare differences between the means. A general linear model was used to identify the AD patients' characteristics that independently affected the survival time from NHP to death (Table 2 ). The following potential predictors were investigated: sex, living alone (yes/no), age, years of education, cognitive ability, instrumental and basic ADL capacities at NHP, rates of decline in cognition and function, number of concomitant medications, and type of ChEI, dose, and duration of treatment. The SATS patients' time spent in NHs are shown separately for men and women. In the figure, time was rounded to the nearest integer year. The mean ± standard deviation (SD) length of time in NHs was 4.06 ± 2.77 years. Men with AD spent a shorter time in NHs than did women: 2.78 ± 2.29 years vs. 4.53 ± 2.79 years, respectively (p < 0.001). No sex difference was observed in age at AD onset, illness duration, age at diagnosis, time between diagnosis and NHP, age at NHP, and age at death.
Mean age at AD onset, age at diagnosis, age at NHP, and age at death in the three groups of SATS participants grouped according to their basic ADL performance at NHP. The individuals who exhibited a PSMS score of 6-9 at NHP spent a longer time in NHs (mean ± SD, 4.4 ± 2.9 years) than did those who had a PSMS score of 15-30 (3.0 ± 2.1 years, p = 0.020). No difference in survival time in NHs was observed between patients with no basic ADL impairment (PSMS score of 6) at NHP and those with a PSMS score of 7-9. Worse basic ADL capacity at NHP and a longer time between AD diagnosis and NHP also showed a significant relationship (p = 0.021). The group with a PSMS score of 10-14 was younger at AD onset than that with a PSMS score of 15-30 (p = 0.034). No differences were found in illness duration, age at diagnosis, age at NHP, and age at death between the three groups. Mean age at AD onset, age at diagnosis, age at NHP, and age at death according to the interaction effect of sex by living status. Men living with a family member spent less time in NHs (mean ± SD, 2.2 ± 2.1 years) compared with the other groups: women living with family (4.8 ± 2.8 years); men living alone (4.0 ± 2.2 years); and women living alone (4.4 ± 2.8 years, p < 0.001). Moreover, men living with family had a longer mean time from AD diagnosis to NHP (1.9 ± 0.7 years) than did women living alone (1.5 ± 0.9 years, p = 0.022). No significant differences were detected in the age at AD onset, illness duration, age at diagnosis, age at NHP, and age at death.
Mean age at AD onset, age at diagnosis, age at NHP, and age at death in the three groups of participants grouped according to the number of medications at the time of AD diagnosis (start of ChEI therapy). The patients who received 0-2 medications spent a longer time in NHs (mean ± SD, 4.5 ± 2.6 years) compared with those who received 3-6 or ≥7 medications (3.7 ± 3.0 years and 3.1 ± 2.4 years, respectively, p = 0.044). Taking more medications at the time of diagnosis was significantly associated with older age at AD onset (p = 0.009), shorter illness duration (p = 0.022), and older age at diagnosis (p = 0.043) and at NHP (p = 0.043). No differences were detected in the time between AD diagnosis and NHP, and age at death between the three groups. 
RESULTS
The interaction effect of sex by living status, basic ADL impairment at NHP, and number of concomitant medications were independent predictors of survival time in NHs. Age, years of education, cognitive ability or instrumental ADL capacities at NHP, rate of decline in cognition or function, and type of ChEI, dose, and treatment duration were not significant variables in the multivariate model. CI, confidence interval; NHP, nursing home placement; PSMS, Physical Self-Maintenance Scale. Estimated age at onset of AD, years 73.5 ± 6.9
Estimated duration of AD, years 3.4 ± 2.6 5.1 ± 2.7
Age, years 76.9 ± 5.9 78.6 ± 5.8
Education, years 9.2 ± 2.3 MMSE score 20.1 ± 4.0 17.5 ± 5.7
IADL score 18.3 ± 5.1 22.7 ± 4.7 PSMS score 8.2 ± 2.8 10.5 ± 3.9
Number of concomitant medications 3.0 ± 2.4
Mean dose of ChEI during the SATS, mg Donepezil (n = 138) 6.8 ± 1.8
Rivastigmine (n = 37) 5.7 ± 1.9
Galantamine (n = 45) 15.1 ± 3.2
Time from start of ChEI therapy to NHP, months 19.5 ± 10.0
Age at death, years 82.6 ± 6.0
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The interaction effect of sex by living status, basic ADL impairment at NHP, and number of concomitant medications were independent predictors of survival time in
NHs. Age, years of education, cognitive ability or instrumental ADL capacities at NHP, rate of decline in cognition or function, and type of ChEI, dose, and treatment duration were not significant variables in the multivariate model.
The data are expressed as either number (percentage) or mean ± standard deviation. AD, Alzheimer's disease; ChEI, cholinesterase inhibitor; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NHP, nursing home placement; PSMS, Physical Self-Maintenance Scale; SATS, Swedish Alzheimer Treatment Study.
